pharma · Dravet syndrome · Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
Biocodex
Biocodex is a pharma organization headquartered in GENTILLY, FR. Primary therapeutic focus areas include Dravet syndrome, Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3), Non-constipated Irritable Bowel Syn
Gentilly, FR HQ
1953 Founded
1,648 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Gentilly, FR
- Founded
- 1953
- Employees
- 1,648
- Programs
- 5
- Drugs
- 15
- Patents
- 25
Sb 241
Approved · small molecule · Patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis))
Sb 241 for Patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis)) is a Approved program (small_molecule) at Biocodex with 1 ClinicalTrials.gov record(s).
Internal code Sb 241
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Biocodex
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis))
- Status
- active
- Trials
- 1